The government has set aside £11.8bn to compensate victims of the infected blood scandal, after a public inquiry found the ...

Novo Nordisk has shared positive results from a late-stage study of its investigational haemophilia A therapy Mim8 in ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/19.CcrFU5Zy.js ...

Novo Nordisk’s bispecific antibody Mim8 prevented bleeding events and caused no adverse safety events in the Phase III ...

The liver is the site of synthesis of all clotting factors except factor VIII; therefore in liver disease there will be prolonged values due to a lack of factor production. Transfusing the patient ...

Thus, although the reduced production of most clotting factors in patients ... coupled with increased von Willebrand factor and factor VIII levels, increases the risk of coagulopathy.

Novo Nordisk today announced interim results from the phase 3 FRONTIER3 trial of 70 children (aged 1-11 years old) with haemophilia A with and without inhibitors. The trial initially assessed ...

Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis experienced zero treated ...

Antibody therapy Mim8 was found to be safe and effective for controlling bleeds in children with hemophilia A in a Phase 3 ...

According to research presented at the EAHAD 2024 Annual Congress, a new classification system enhances diagnosis and ...